Safety profile of new anticancer drugs

作者: Laura Mansi , Antoine Thiery-Vuillemin , Thierry Nguyen , Fernando Bazan , Fabien Calcagno

DOI: 10.1517/14740330903530663

关键词:

摘要: Importance of the field: The development targeted anticancer therapies stems from advances in molecular biology. New agents range antibodies that form complexes with antigens on surface cancer cell to small molecules have been engineered block key enzymatic reactions. interaction antibody or drug its target inhibits pathways involved proliferation metastasis, activates leading death. Such constitute ideal pharmacological targets. Clinical benefits these novel therapeutic strategies are striking for patients metastatic diseases.Areas covered: This review analyses main toxicities among most common approved by FDA European Medicines Agency their clinical utilisation solid tumours treatment.What reader will gain: Here, toxicity and safety data new described. Data organised through t...

参考文章(193)
David A. Tuveson, George D. Demetri, Anette Duensing, Sheng Xiao, Brian P. Rubin, Christopher D. M. Fletcher, Connie Tsao, Marcia L. Lux, Michele K. Hibbard, Samuel Singer, Jonathan A. Fletcher, Robert Ruiz, Chang-Jie Chen, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Research. ,vol. 61, pp. 8118- 8121 ,(2001)
Charles M. Rudin, Wanqing Liu, Apurva Desai, Theodore Karrison, Xuemin Jiang, Linda Janisch, Soma Das, Jacqueline Ramirez, Balasubramanian Poonkuzhali, Erin Schuetz, Donna Lee Fackenthal, Peixian Chen, Deborah K. Armstrong, Julie R. Brahmer, Gini F. Fleming, Everett E. Vokes, Michael A. Carducci, Mark J. Ratain, Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity Journal of Clinical Oncology. ,vol. 26, pp. 1119- 1127 ,(2008) , 10.1200/JCO.2007.13.1128
Eric Van Cutsem, Marc Peeters, Salvatore Siena, Yves Humblet, Alain Hendlisz, Bart Neyns, Jean-Luc Canon, Jean-Luc Van Laethem, Joan Maurel, Gary Richardson, Michael Wolf, Rafael G. Amado, Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 25, pp. 1658- 1664 ,(2007) , 10.1200/JCO.2006.08.1620
Ezra E. W. Cohen, Fred Rosen, Walter M. Stadler, Wendy Recant, Kerstin Stenson, Dezheng Huo, Everett E. Vokes, Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Journal of Clinical Oncology. ,vol. 21, pp. 1980- 1987 ,(2003) , 10.1200/JCO.2003.10.051
Lee S. Schwartzberg, Edward J. Stepanski, Mark S. Walker, Susan Mathias, Arthur C. Houts, Barry V. Fortner, Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Supportive Care in Cancer. ,vol. 17, pp. 91- 98 ,(2009) , 10.1007/S00520-008-0474-5
David R. D'Adamo, Sibyl E. Anderson, Karen Albritton, Jennifer Yamada, Elyn Riedel, Kelly Scheu, Gary K. Schwartz, Helen Chen, Robert G. Maki, Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas Journal of Clinical Oncology. ,vol. 23, pp. 7135- 7142 ,(2005) , 10.1200/JCO.2005.16.139
Michael B. Atkins, Manuel Hidalgo, Walter M. Stadler, Theodore F. Logan, Janice P. Dutcher, Gary R. Hudes, Young Park, Song-Heng Liou, Bonnie Marshall, Joseph P. Boni, Gary Dukart, Matthew L. Sherman, Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology. ,vol. 22, pp. 909- 918 ,(2004) , 10.1200/JCO.2004.08.185
Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Negrier, Cezary Szczylik, Roberto Pili, Georg A. Bjarnason, Xavier Garcia-del-Muro, Jeffrey A. Sosman, Ewa Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin, Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Journal of Clinical Oncology. ,vol. 27, pp. 3584- 3590 ,(2009) , 10.1200/JCO.2008.20.1293
M. Moore, H.W. Hirte, L. Siu, A. Oza, S.J. Hotte, O. Petrenciuc, F. Cihon, C. Lathia, B. Schwartz, Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors Annals of Oncology. ,vol. 16, pp. 1688- 1694 ,(2005) , 10.1093/ANNONC/MDI310
Tammy F Chu, Maria A Rupnick, Risto Kerkela, Susan M Dallabrida, David Zurakowski, Lisa Nguyen, Kathleen Woulfe, Elke Pravda, Flavia Cassiola, Jayesh Desai, Suzanne George, David M Harris, Nesreen S Ismail, Jey-Hsin Chen, Frederick J Schoen, Annick D Van den Abbeele, George D Demetri, Thomas Force, Ming Hui Chen, Jeffrey A Morgan, Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib The Lancet. ,vol. 370, pp. 2011- 2019 ,(2007) , 10.1016/S0140-6736(07)61865-0